ACE2 and metabolic disease: Several previous studies have tested the role of the systemic delivery of ACE2/Ang(1–7) in clinics to treat RAS-associated metabolic diseases or COVID-19 infection that significantly impacts the RAS pathway [63,64,65,66,67,68,69,70].